$5000 | Single User
$7500 | Site License
$9000 | Global License

EPIOMIC EPIDEMIOLOGY SERIES: CHRONIC HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2018–2028 [Report Updated: 01-12-2017]

Published by Black Swan Analysis: 01 Dec 2017 | 196010 | In Stock

Introduction

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Chronic Heart Failure in 12 Major Markets

Chronic heart failure (CHF) is a chronic disease during which the heart is not able to supply sufficient blood flow to the body. Exacerbations of CHF are characterised by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs. The disease is associated with toxic, inflammatory and infective heart damage, structural, metabolic and genetic heart abnormalities, as well as cardiovascular risk factors, such as smoking, sedentary lifestyle, unhealthy diet and alcohol consumption.

This report provides the current prevalent population for chronic heart failure across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, Brazil & India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, patient populations with the two types of chronic heart failure, as well as several of the main symptoms and co-morbidities of chronic heart failure have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for chronic heart failure include:

• Arterial hypertension

• Coronary artery disease

• Atrial fibrillation

• Diabetes mellitus

• Metabolic syndrome

• Obesity

• Renal dysfunction

• Chronic obstructive pulmonary disease (COPD)

• Pulmonary hypertension

• Sleep apnoea

• Anaemia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global chronic heart failure market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of chronic heart failure and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on chronic heart failure’s prevalent population.

• Identify sub-populations within chronic heart failure which require treatment.

• Gain an understanding of the specific markets that have the largest number of chronic heart failure patients.

Table of Contents
for EPIOMIC EPIDEMIOLOGY SERIES: CHRONIC HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2018–2028 [Report Updated: 01-12-2017]

  • CONTENTS

    • LIST OF TABLES AND FIGURES

    • INTRODUCTION

    • CAUSE OF THE DISEASE

    • RISK FACTORS & PREVENTION

    • DIAGNOSIS OF THE DISEASE

    • VARIATION BY GEOGRAPHY/ETHNICITY

    • DISEASE PROGNOSIS & CLINICAL COURSE

    • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

    • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

    • TOP-LINE PREVALENCE FOR CHRONIC HEART FAILURE

    • CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION

    • FEATURES OF CHF-REF PATIENTS

    • COMORBID CONDITIONS OF CHF-REF PATIENTS

    • CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION

    • FEATURES OF CHF-PEF PATIENTS

    • COMORBID CONDITIONS OF CHF-PEF PATIENTS

    • ABBREVIATIONS USED IN THE REPORT

    • OTHER BLACK SWAN ANALYSIS PUBLICATIONS

    • BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES

    • PATIENT-BASED OFFERING

    • ONLINE PRICING DATA & PLATFORMS

    • REFERENCES

    • APPENDIX

    LIST OF TABLES AND FIGURES

    • Table 1. Aetiologies of Heart Failure

    • Table 2. Symptoms and Signs Typical of Heart Failure

    • Table 3. Classification and Common Clinical Characteristics of Patients with Acute Heart Failure

    • Table 4. NYHA Classification of Heart Failure

    • Table 5. Clinical-hemodynamic Profiles of Heart Failure (following Stevenson et al)

    • Table 6. Markers of Worse Prognosis in Patients with Heart Failure

    • Table 7. Prevalence of Chronic Heart Failure, total (000s)

    • Table 8. Prevalence of Chronic Heart Failure, males (000s)

    • Table 9. Prevalence of Chronic Heart Failure, females (000s)

    • Table 10. Prevalence of CHF-REF, total (000s)

    • Table 11. Prevalence of CHF-REF, males (000s)

    • Table 12. Prevalence of CHF-REF, females (000s)

    • Table 13. CHF-REF Patients by NYHA Class, total (000s)

    • Table 14. CHF-REF Patients with Diabetes, total (000s)

    • Table 15. CHF-REF Patients with COPD, total (000s)

    • Table 16. CHF-REF Patients with Anaemia, total (000s)

    • Table 17. CHF-REF Patients with Atrial Fibrillation, total (000s)

    • Table 18. CHF-REF Patients with Coronary Artery Disease, total (000s)

    • Table 19. CHF-REF Patients with previous Myocardial Infarction, total (000s)

    • Table 20. CHF-REF Patients with Muscle Wasting, total (000s)

    • Table 21. Prevalence of CHF-PEF, total (000s)

    • Table 22. Prevalence of CHF-PEF, males (000s)

    • Table 23. Prevalence of CHF-PEF, females (000s)

    • Table 24. CHF-PEF Patients by NYHA Class, total (000s)

    • Table 25. CHF-PEF Patients with Diabetes, total (000s)

    • Table 26. CHF-PEF Patients with COPD, total (000s)

    • Table 27. CHF-PEF Patients with Anaemia, total (000s)

    • Table 28. CHF-PEF Patients with Atrial Fibrillation, total (000s)

    • Table 29. CHF-PEF Patients with Coronary Artery Disease, total (000s)

    • Table 30. CHF-PEF Patients with previous Myocardial Infarction, total (000s)

    • Table 31. CHF-PEF Patients with Muscle Wasting, total (000s)

    • Table 32. Abbreviations and Acronyms used in the report

    • Table 33. USA Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 34. USA Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 35. Canada Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 36. Canada Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 37. France Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 38. France Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 39. Germany Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 40. Germany Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 41. Italy Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 42. Italy Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 43. Spain Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 44. Spain Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 45. UK Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 46. UK Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 47. Japan Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 48. Japan Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 49. China Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 50. China Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 51. Russia Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 52. Russia Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 53. Brazil Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 54. Brazil Prevalence of CHF by 5-yr age cohort, females (000s)

    • Table 55. India Prevalence of CHF by 5-yr age cohort, males (000s)

    • Table 56. India Prevalence of CHF by 5-yr age cohort, females (000s)

List Of Tables
in EPIOMIC EPIDEMIOLOGY SERIES: CHRONIC HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2018–2028 [Report Updated: 01-12-2017]

See Table of Contents

List Of Figures, Charts and Diagrams
in EPIOMIC EPIDEMIOLOGY SERIES: CHRONIC HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2018–2028 [Report Updated: 01-12-2017]

See Table of Contents

Additional Details

Publisher

Black Swan Analysis

Publisher Information

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.



The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.



We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.



The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.



Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Reference

196010 | CRHF0011217

Number of Pages

58

Report Format

PDF

Black Swan Analysis Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Epiomic Epidemiology Series: Huntington's Disease Forecast in 8 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Huntington’s disease in 8 Major ...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Uveitis Forecast in 10 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Uveitis in 10 Major MarketsUveit...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Onychomycosis Forecast in 10 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Onychomycosis in 10 Major Market...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Wegener's Granulomatosis Forecast in 9 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Wegener’s Granulomatosis in 9 Ma...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 8 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Retinal Vein Occlusion in 8 Majo...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Hypertrophic Cardiomyopathy Forecast in 8 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hypertrophic cardiomyopathy in 8...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Pulmonary Hypertension Forecast in 8 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Pulmonary Hypertension in 8 Majo...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Cystic Fibrosis Forecast in 9 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Cystic Fibrosis in 9 Major Marke...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Nocturia Forecast in 8 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Nocturia in 8 Major MarketsNoctu...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info
Epiomic Epidemiology Series: Gaucher's Disease Forecast in 9 Major Markets 2015-2025
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gaucher’s Disease in 9 Major Mar...
11 Aug 2015 by Black Swan Analysis USD $6,100 More Info

This report is published by Black Swan Analysis

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.

The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.

We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.

The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.

Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Download Free Report Summary PDF

EPIOMIC EPIDEMIOLOGY SERIES: CHRONIC HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2018–2028 [Report Updated: 01-12-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data